Inclusion Criteria:  Capable of giving signed informed consent Male or female of 18 years of age or older when informed consent is obtained Has a histologically proven Grade 1 or 2 GEP-NET according to WHO (World Health Organisation) classification Has an unresectable metastatic or locally advanced NET. Has an Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 2.  Exclusion Criteria:  Participants with poorly differentiated Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), high-grade GEP-NEC and goblet cell carcinoid. Has been treated with octreotide acetate long-acting release or lanreotide acetate Autogel formulation within 8 weeks prior to screening tests or lanreotide PR 40 mg within 4 weeks prior to screening tests. Has been treated with subcutaneous or intravenous octreotide acetate within 1 week prior to screening tests. Has been treated with mammalian target of rapamycin (mTOR) inhibitors or multi-target tyrosine kinase (MTK) inhibitors within 4 weeks prior to screening tests.